Good day, all Bitcointalk members!
We are pleased to present our project to you!
Advanced Pharma Intelligence on Blockchain
ICO STARTING AUGUST 21th, 08.08 PM UCT - 20% Bonus first two weeks
We apologize for not being able to have a full announcement of our project. Due to member status limitations we are not allowed to post pictures yet.
See our presentation video here:
www.biotechintel.com/videosHomepage:
www.biotechintel.comWhitepaper:
www.biotechintel.com/whitepaperFAQ:
www.biotechintel.com/faq/Team:
www.biotechintel.com/team/Token Sale:
http://www.biotechintel.com/token-sale/
SummaryStructure and platformIncorporation Status: ADVANCED PHARMA INTELLIGENCE GMBH
Location: ZUG, SWITZERLAND
Team : TRANSPARENT IDENTITIES
Technical White Paper: TECHNICAL AND PLATFORM
Beta Version: DRUG PRICING BETA VERSION
Proof of concept: DRUG FORECASTING PLATFORM
Mobile app: PROJECT X ? TO BE PATENTED
Trading platform : ARCHITECURE PLAN
Token DescriptionToken name: BioNT
Allocation: 140,000,000 TOKENS
Token Sale period: 21.08.2017 08:00PM UTC TILL 23.10.2017 08:00PM UTC
Unsold Tokens: SUBJECT TO LOCKUP OF 5 YEARS
Bonus Weeks 1 to 4: 1ST+2ND WEEK 20%, 3RD WEEK 15%, 4TH WEEK 10%, 5TH WEEK 5%
Week 6 - 9 : FINISHING OCTOBER 23, 2017, NO BONUS TOKENS
Introduction
Industry Background- 7,000 drugs in development
- Industry set to grow from $800 Billion to $1.2 Trillion globally by 2020
- Generic, Pharmaceutical and Biotech remain in the top ten most profitable industries in the world
- With so many drugs in discovery, how do you bet on the break through, and the financially profitable ones?
The global Pharma and Biotech Industry ranks high among the most profitable industries in the world. The current market is estimated to grow from $800 Billion USD to $1.2 Trillion by 2022. The market cap of the top 100 pharmaceutical companies is $2.2 Trillion dollars.
Problems with current pharma and biotech drug pricing and financial forecastingMcKinsey confirms pharma forecasts fragile, the extent of imprecision is truly remarkable.
1. Commercially driven forecasts to secure budgets and investment
2. The internal silo impact reducing efficiency and accuracy
3. Lack of integration of pricing & reimbursement assumptions and the probability of pricing & reimbursement outcomes
4. Not using common global language across entire organization
5. Limited capabilities within the organization
6. Ignoring impact of data sources & external events, lack of catalogued references and assumptions
To improve outcomes and capabilities, companies need to integrate real-time accounts of their judgments, underlying assumptions, data sources, external events including trends in reimbursement.
Key drivers behind forecast failures are poor assumptions
There's no chance that the iPhone will gain any significant market share? Steve Ballmer, Microsoft 2007
New product forecasting (NPF) is inherently difficult, usually inaccurate, and past analogues do not incorporate emerging trends. ?It's not what we know that leads to poor forecasting outcomes; its what we knew, ignored and didn't communicate? Global biotech forecaster, 2014
Our Solution and Development Roadmap to Drug Discovery- Global Drug Pricing
- Global Disease and Epidemiology
- Clinical Trial Outcomes and Approvals
- Advanced Pharma Intel Algorithm
- Market and Drug Performance
The global drug pricing platform is designed to retrieve drug prices from global disparate sources. Sources are both public/government and private sources. The initial focus will be Oncology and Orphan diseases, paving the way for price setting and trends for new combination therapies.
Epidemiology data bank will store patient treatment pathways for key diseases, the data bank will also be populated with patient numbers to link new molecules to market potential.
Tracking both historical and upcoming outcomes and approvals will enable the platform to predict and report the sensitivity analysis. The key data blocks linked with historical data, will allow Advanced Pharma Intelligence not only the ability to deliver analysis to front end clients, but also the algorithm to predict outcomes based on Phase I and Phase II outcomes data.
Who we are, and what we do- Seasoned team of industry experts based in Zug, Switzerland
- Combining industry, pricing, software and trading knowledge
- Translate global data into a single non-biased fact-based platform
- Seek and identify the highest profitable molecules in clinical development
The Problem- There are 7,000 drugs in development, and 70% of those will be first in class
- Only 2 out of 10 drugs match or exceed R&D investment4
- Evaluate Pharma lowers projections for next 5 years by $390 billion mainly due to pricing pressure
- Forecasting is becoming more and more complex due to bio-markers and orphan indications
- Trading and stock price volatility has been increasing as a result
Our Solution- Single global drug pricing platform
- Disease and epidemiology database
- Drug forecasting platform
- Integrated drug pricing and forecasting system through Blockchain
- Securities trading signals
Our Roadmap- Development of scalable drug pricing system
- Commercialization of the drug pricing system
- Development and commercialization of the drug forecasting system
- Development of the X-App
- Development of the securities trading signals
The BioNT Token- 140,000,000 BioNT Tokens
- 5-year lock up of unsold tokens
- 50% of annual software revenues for token buy back
a. Those tokens will be deleted after buyback
Development Road Map The development and commercialization of the three core projects will be subject to the level of funding secured. The timeline outlined for development and delivery seeks to maximize both development and commercialization.
The X-APP will be detailed post development and prior to commercialization. The APP will provide a hub to link and retrieve global data for the platforms described above.
Development Phasing1 Develop & Commercialize the Drug Pricing Platform - 3 months
2 Develop Drug Forecasting Platform - 4-8 months
X Develop APP-X Global Data Sourcing App - TBC
3 Develop Trading Platform - 8-16 months
Investment Allocation- Development of trading Platform - 25%
- Development of Drug Forecasting Platform - 20%
- Global Marketing & Sales Phase 1 - 10%
- Global Marketing & Sales Phase 2 - 10%
- Merge Pricing and Forecasting Platform - 10%
- Enhancement of, and Commercialization Beta Pricing Platform - 10%
- Team Allocation - 10%
- Legal - 5%
BioNT TokenToken ICO starting 21-08-2017, at 08.08pm UTC, until sold out or till end of ICO period.
- 1st + 2nd weeks 20% additional tokens
- 3rd week 15% additional tokens
- 4th week 10% additional tokens
- 5th week 5% additional tokens
- 6th/9th week, finishing 23-10-2017, at 08.08pm UTC, no bonus tokens
Token Name: BioNT
Fixed Price: 300 BioNT per ETH
Issuing Entity: Advanced Pharma Intelligence GmbH
Jurisdiction of Issuance: Switzerland
Time to Issuance: Tokens are issued immediately to your Ether Wallet were you hold your private key. However, Tokens will have a transfer freeze until the tokens are listed on exchanges.
If any tokens left after that period, these ¨unsold tokens¨ will be held in ¨Treasury¨ of the Advanced Pharma Intelligence GmbH, available for a sale in secondary market, but with a lockup of 1825 days, basically five years (5*365), hard coded in the smart contract.
The number of tokens are capped, 140 million, (the maximum amount raised does depend on the additional bonus tokens in the first few weeks of the offering, this is automatically done in the smart contract settings too).
126 million tokens available for the crowdsale campaign.
14 million tokens, with a 6 month lock up, are reserved for Advanced Intelligence GmbH and founders team.
Advanced Pharma Intelligence GmbH develops and enhances its systems (existing and planned new systems) and business development (commercialization of existing beta tested and to be developed ones).
Advanced Pharma Intelligence GmbH will buy in the secondary market, both on the exchanges as well as in direct deals with participants at a price not exceeding the then market price, a minimum of 50%of the software revenues each year, for 25 years, those tokens will be deleted (¨irreversibly moved to trash¨) after buyback. This will be done in the second month after the year was finished, i.e. February 2018/2041. Announcement of how many tokens at what average price have been bought back will follow one month after the completion of those buybacks.
In February/April 2042, buyback in the open market will be done for a three-month period, and the total sum of buybacks will be divided by the number of still outstanding/not bought back tokens (possibly including any tokens that are still in the Treasury of Advanced Pharma Intelligence GmbH and haven't been sold in a secondary offering). If any tokens haven't been offered for sale at the secondary market, management of Advanced Pharma Intelligence GmbH will donate the remainder of the monies to a good cause of their choice (one or more not-for profit charitable organizations, e.g. World Cancer Research Fund, Red Cross).
In exceptional cases, in order to provide the most risk averse features, we may upgrade the smart contract code and update and transparently send the new valid token, e.g. in case the exchanges, where we'd like to list, demand such.
Gas limit is responsibility of the sender/contributor.
In case the cap (126 million tokens for sale in crowdsale) is reached, excess payments will be rejected and repaid.
Feel free to ask any questions.
Advanced Pharma Intelligence GmbH
